Triple GLP-1/GIP/glucagon agonist · phase 3 complete · up to 28.3% weight loss at 80 weeks (30.3% at 2 years)
The ReferenceBenefits, protocols and preparationOpen the reference →What this peptide does at the cellular level, in plain words.
First of the three receptors. Satiety and glycemic control.
Second receptor. Synergizes with GLP-1 to amplify metabolic effect.
Third receptor. Increases energy expenditure and fat oxidation.
Phase 3 (TRIUMPH-1, 2026): up to 28.3% of body weight at 80 weeks and 30.3% at 2 years. Category record.

Lose weight & curb appetite
RetaLeanRetatrutideLowers body weight · Controls appetite and satiety
+ EnergyDriveMOTS-c+ Adds: Preserves and protects muscle
+ CagriFit+CagrilintideReinforces: Lowers body weight
+ TesaFit+TesamorelinReinforces: Reduces visceral belly fat
RetaLean + CagriFit+Retatrutide + CagrilintideOn its own or alongside a GLP-1 (retatrutide or tirzepatide): it adds satiety through another pathway (amylin + GLP-1), boosts the effect and helps break a plateau.
RetaLean + EnergyDriveRetatrutide + MOTS-cAlongside a GLP-1 it preserves the muscle lost while losing weight.
RetaLean + TesaFit+Retatrutide + TesamorelinWith a GLP-1 it targets the visceral belly fat the scale cannot tell apart.Retatrutide (also known as LY3437943) is the first triple agonist peptide in the GLP-1 class, targeting GLP-1, GIP and glucagon receptors with a single molecule. It completed its first phase 3 trials with Eli Lilly (TRIUMPH program, 2025-2026) and is not yet approved: it is the frontier of metabolic peptide research.
SuperBio Labs Retatrutide is provided as lyophilized powder, ≥99% pure by HPLC, with full LC-MS sequence confirmation. Each batch is supplied with an independent Certificate of Analysis covering purity, peptide content (98–102%), endotoxin levels (<1.0 EU/mg), and residual solvents.
The triple agonist mechanism sets retatrutide apart from single (semaglutide) and dual (tirzepatide) agonists: the glucagon receptor raises energy expenditure and fat burning, while GLP-1 + GIP reduce appetite and improve insulin sensitivity. In phase 3 it reached up to 28.3% weight reduction at 80 weeks on 12 mg (TRIUMPH-1, 2,339 adults; 30.3% at 104 weeks in severe obesity) and 28.7% at 68 weeks in the osteoarthritis trial (TRIUMPH-4). In the osteoarthritis trial (TRIUMPH-4) knee pain fell 75.8% (4.5 WOMAC points; more than 1 in 8 became pain-free) and in the TRIUMPH-1 knee basket, 73.1%; in moderate-to-severe sleep apnea breathing pauses per hour fell 60.6% (36 fewer events per hour). With type 2 diabetes it lost up to 20.8% and cut A1C by 1.5 points (TRIUMPH-2); with severe obesity and cardiovascular disease, 22.6%, with triglycerides −37% and systolic blood pressure −9 mmHg (TRIUMPH-3). Major cardiovascular events were fewer than with placebo (ratio 0.82) without reaching significance: the dedicated cardiovascular trial (TRIUMPH-Outcomes) reports around 2028–2029. Lilly will file for approval in the first quarter of 2027. What the GLP-1 class has already shown and retatrutide has not yet measured: heart and kidney outcomes (TRIUMPH-Outcomes, around 2029), biopsy-proven liver inflammation (phase 3 announced), psoriasis and alcohol (no trial). The rest — weight, knee, apnea, glucose, lipids, blood pressure and inflammation — it already holds in its own right.
Informed professional research use only.
We don't just hand you the vial. Every Retatrutide purchase includes everything you need to apply it safely, with a clear protocol and our team available 24/7.
Lyophilized · HPLC purity ≥99% · Batch with COA
Sterile diluent · 0.9% benzyl alcohol
21G needle · For peptide reconstitution
10mg → 5 · 20mg → 10 · 1×/week
10mg → 6 · 20mg → 11 · 1 per application + 1 to reconstitute
Free app · Week-by-week protocol, product sheet and usage guide
8 steps · From opening the kit to application
App · Tracking · Human team 24/7
About supplies: the quantity of syringes and wipes adjusts automatically based on the presentation you choose. For extended cycles (BPC-157, GHK-Cu and similar) we cap supplies at 30 days — beyond that, 29G insulin syringes and 70% alcohol wipes are pharmacy items available without prescription in any city.
This product meets all five — your batch COA ships with the kit.
The official protocol included in the kit. If you have pre-existing medical conditions, consult a professional before starting.
Wk 1–4: 1.5 mg → Wk 5–8: 2 mg → Wk 9–12: 2.5 mg → Wk 13–16: 3 mg
Triple agonist GLP-1 + GIP + glucagon. Frontier molecule.
The largest reduction recorded in its class (TRIUMPH-1: up to 28.3% at 80 weeks and 30.3% at 2 years).
Liver fat −82% in the phase 2 substudy.
Waist, triglycerides, blood pressure and glucose together (TRIUMPH-3).
Glucagon adds energy expenditure · switch one for the other, never both.
TRIUMPH-4: knee pain −75.8% and more than 1 in 8 pain-free, together with −28.7% weight.
With strength training, high protein, MOTS-c and tesamorelin · see Recomposition · Reta.
Moderate-to-severe apnea: 60.6% fewer pauses per hour (36 fewer events) in phase 3.
The GLP-1 profile, stronger, plus one effect of its own. In TRIUMPH-1 (2,339 adults; 4, 9 and 12 mg): nausea 29–42%, diarrhea 25–34%, constipation 24–26%, vomiting 11–25% (placebo 5–15%). Mostly mild or moderate and concentrated during dose escalation.
Specific to retatrutide: dysesthesia (tingling or sensitive skin) in 5% at 4 mg, 12% at 9 mg and 12.5% at 12 mg in TRIUMPH-1 (up to 20.9% at 12 mg in TRIUMPH-4), almost always mild and usually resolving without stopping treatment. In phase 2, heart rate rose by a few beats in the first weeks. Discontinuation due to adverse events was 4% at 4 mg, 7% at 9 mg and 11% at 12 mg (placebo 5%), which is why we titrate slowly. In TRIUMPH-2 and TRIUMPH-3 dysesthesia was 4.5–7.3% and 6.4% versus 0.7–1.3% on placebo. Two class notices: if you are having surgery or an endoscopy under sedation, say you use a GLP-1 (slow gastric emptying; FDA label, Nov 2024); and seek care at once for sudden vision loss (NAION, "very rare" with semaglutide per the EMA, Jun 2025). If you vomit or have diarrhea, hydrate: dehydration can harm the kidney. Do not use with prior pancreatitis, medullary thyroid cancer or MEN2, pregnancy, or together with another GLP-1.
| CAS number | 2381089-83-2 |
| Molecular weight | 4731 Da |
| Purity (HPLC) | ≥99% |
| Format | Lyophilized powder |
| Quantity | 10 / 20 mg per vial |
| Endotoxins | <1.0 EU/mg |
| Storage | −20 °C, protected from light |
| Use | Use under professional judgment |